| scholarly article | Q13442814 |
| P50 | author | Manel Esteller | Q3816008 |
| Miguel Alaminos | Q57014203 | ||
| Veronica Davalos | Q62763648 | ||
| Nai-Kong V Cheung | Q88954512 | ||
| P2093 | author name string | William L Gerald | |
| P2860 | cites work | The EMBL Nucleotide Sequence Database | Q24548433 |
| Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands | Q24631957 | ||
| Altered HOX and WNT7A expression in human lung cancer | Q24679566 | ||
| Structure of HoxA9 and Pbx1 bound to DNA: Hox hexapeptide and DNA recognition anterior to posterior | Q27641842 | ||
| Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 | ||
| Gene expression profiling predicts clinical outcome of breast cancer | Q27860732 | ||
| A gene-expression signature as a predictor of survival in breast cancer | Q27860945 | ||
| The MEIS1 oncogene is highly expressed in neuroblastoma and amplified in cell line IMR32 | Q28143160 | ||
| Gene silencing in cancer in association with promoter hypermethylation | Q29617274 | ||
| Cancer epigenetics comes of age | Q29617275 | ||
| A role for distinct cell types in determining malignancy in human neuroblastoma cell lines and tumors | Q31150761 | ||
| CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future | Q33337445 | ||
| Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells | Q33773096 | ||
| Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group | Q33876841 | ||
| Screening of infants and mortality due to neuroblastoma | Q34122052 | ||
| Neuroblastoma: biological insights into a clinical enigma | Q34180699 | ||
| Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. | Q34197920 | ||
| Molecular genetics of neuroblastoma and the implications for clinical management: a review of the MSKCC experience | Q34292209 | ||
| Genomic medicine and neuroblastoma. | Q35045279 | ||
| Relevance of DNA methylation in the management of cancer | Q35146155 | ||
| Retinoid therapy of high-risk neuroblastoma. | Q35184993 | ||
| Neuroblastoma: biology and molecular and chromosomal pathology | Q35193677 | ||
| Quantitative GSTP1 Methylation and the Detection of Prostate Adenocarcinoma in Sextant Biopsies | Q35576603 | ||
| Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes | Q35791618 | ||
| Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP). | Q36292918 | ||
| Spatial association of apoptosis-related gene expression and cellular death in clinical neuroblastoma | Q36420181 | ||
| Clustering of hypermethylated genes in neuroblastoma | Q40631838 | ||
| Molecular epidemiology and retinoid chemoprevention of head and neck cancer | Q41337370 | ||
| A novel methodology for the establishment of neuroblastoma cell lines from metastatic marrow. Expression of surface markers, neurofilaments, MDR-1 and myc proteins | Q41629646 | ||
| Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. | Q43805317 | ||
| Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer | Q44474020 | ||
| Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases | Q44547361 | ||
| Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers. | Q44594521 | ||
| Nucleolar size indicates the rapidity of cell proliferation in cancer tissues | Q47236518 | ||
| Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. | Q51028737 | ||
| International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. | Q53319603 | ||
| Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. | Q53417183 | ||
| Neuroblastoma Screening at One Year of Age | Q56637925 | ||
| Phylogenetic Reconstruction Using an Unsupervised Growing Neural Network That Adopts the Topology of a Phylogenetic Tree | Q57837787 | ||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypermethylation | Q106875739 |
| P304 | page(s) | 1208-1219 | |
| P577 | publication date | 2004-08-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma | |
| P478 | volume | 96 |
| Q24801375 | A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation |
| Q28469084 | A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies |
| Q82891679 | A pyrosequencing assay for the quantitative methylation analysis of the PCDHB gene cluster, the major factor in neuroblastoma methylator phenotype |
| Q35904348 | ASC deficiency suppresses proliferation and prevents medulloblastoma incidence |
| Q38784675 | BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways |
| Q33344256 | CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23 |
| Q29615524 | Cancer epigenomics: DNA methylomes and histone-modification maps |
| Q38112248 | Clinical application of the CpG island methylator phenotype to prognostic diagnosis in neuroblastomas |
| Q34743908 | Clinical potentials of methylator phenotype in stage 4 high-risk neuroblastoma: an open challenge. |
| Q35959023 | CpG island methylation of TMS1/ASC and CASP8 genes in cervical cancer |
| Q34722434 | DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. |
| Q36380887 | DNA hypomethylation affects cancer-related biological functions and genes relevant in neuroblastoma pathogenesis |
| Q36056884 | DNA methylation patterns in alcoholics and family controls |
| Q53355958 | Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. |
| Q89967594 | Dual Role of Inflammasome Adaptor ASC in Cancer |
| Q54442349 | Epigenetic alterations in disseminated neuroblastoma tumour cells: influence of TMS1 gene hypermethylation in relapse risk in NB patients. |
| Q36953153 | Epigenetic changes in pediatric solid tumors: promising new targets |
| Q36667457 | Epigenetic diagnostics of cancer--the application of DNA methylation markers |
| Q36356047 | Epigenetic inactivation of the candidate tumor suppressor gene ASC/TMS1 in human renal cell carcinoma and its role as a potential therapeutic target |
| Q37615626 | Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies |
| Q48209723 | Epigenetic regulation of neuroblastoma development |
| Q55010086 | Epigenetics in assisted reproductive technology. |
| Q38290673 | Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma |
| Q39449319 | GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma |
| Q37091263 | Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers |
| Q33578303 | Genome-wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastoma |
| Q58321447 | Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions |
| Q92237783 | Genome-wide DNA methylation profile of early-onset endometrial cancer: its correlation with genetic aberrations and comparison with late-onset endometrial cancer |
| Q36838937 | Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors |
| Q36378134 | Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers |
| Q38996110 | HOXA9 inhibits migration of lung cancer cells and its hypermethylation is associated with recurrence in non-small cell lung cancer |
| Q34483135 | High-throughput DNA methylation profiling using universal bead arrays |
| Q36860601 | Histone modifications as markers of cancer prognosis: a cellular view. |
| Q57732371 | Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease |
| Q53568009 | Hypermethylation of the COX-2 gene is a potential prognostic marker for cervical cancer. |
| Q34029818 | Integrative epigenomic and genomic analysis of malignant pheochromocytoma |
| Q51534604 | MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma. |
| Q37238341 | Methionine depletion with recombinant methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs |
| Q34983345 | Methylation mediated silencing of TMS1/ASC gene in prostate cancer |
| Q30239861 | Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology. |
| Q38088418 | New prognostic markers in neuroblastoma. |
| Q37192430 | No association of TAP1 and TAP2 genes polymorphism with risk of cervical cancer in north Indian population |
| Q36259607 | Pediatric cancer epigenome and the influence of folate |
| Q29622925 | Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer |
| Q39998940 | Prediction of cancer outcome using DNA microarray technology: past, present and future. |
| Q36350870 | Promoter hypermethylation as a mechanism for Lamin A/C silencing in a subset of neuroblastoma cells. |
| Q26744719 | Regulation of Differentiation by Calcium-Sensing Receptor in Normal and Tumoral Developing Nervous System |
| Q64245695 | SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells in Vitro |
| Q36101495 | Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma |
| Q44526270 | The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis. |
| Q42089520 | The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy |
| Q38070334 | The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis |
| Q40269139 | Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. |
| Q35170598 | Two independent epigenetic biomarkers predict survival in neuroblastoma |
Search more.